GlassScriptPhysician profile
Jyh-Haur Lu
NPI 1346313574
$8,952.56
in general payments reported to CMS, 2019-2025
38 companies · $712 in 2025
The $712 reported for 2025 was more than what a typical Neurology (Psychiatry & Neurology) provider received nationally (typical 2025 total: $454).
See the full distribution for Neurology (Psychiatry & Neurology)
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $1,570 · 2020: $893 · 2021: $1,739 · 2022: $1,477 · 2023: $1,481 · 2024: $1,081 · 2025: $712.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $3,273.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $3,273.26 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Neurocrine Biosciences, INC. | $1,196.93 | 2020-2025 | Ingrezza, Ongentys |
| Ucb, INC. | $1,193.18 | 2019-2023 | Nayzilam, Briviact |
| Amneal Pharmaceuticals LLC | $819.46 | 2019-2025 | Crexont, Rytary, Ongentys |
| Sunovion Pharmaceuticals INC. | $552.51 | 2019-2022 | |
| Abbvie INC. | $467.08 | 2019-2025 | |
| Kyowa Kirin, INC. | $416.75 | 2021-2024 | Nourianz |
| Sk Life Science, INC. | $409.05 | 2020-2025 | |
| Mdd US Operations, LLC | $407.96 | 2019-2025 | Gocovri, Gocovri |
| Amgen INC. | $365.15 | 2019-2023 | Aimovig |
| Avanir Pharmaceuticals, INC. | $365.10 | 2019-2022 | |
| Teva Pharmaceuticals USA, INC. | $358.00 | 2019-2025 | Austedo Xr, Austedo Xr, Austedo |
| Adamas Pharmaceuticals, INC. | $260.53 | 2019-2021 | |
| Merck Sharp & Dohme LLC | $209.43 | 2020-2023 | Belsomra |
| Pfizer INC. | $209.31 | 2019-2025 | |
| Supernus Pharmaceuticals, INC. | $176.36 | 2019-2025 | Qelbree |
Show all 38 companies
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Jyh-Haur Lu listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.